Detalhe da pesquisa
1.
Three-year Efficacy and Safety of Takeda's Dengue Vaccine Candidate (TAK-003).
Clin Infect Dis
; 75(1): 107-117, 2022 08 24.
Artigo
Inglês
| MEDLINE | ID: mdl-34606595
2.
Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet Glob Health
; 12(2): e257-e270, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-38245116
3.
Protection against tick-borne encephalitis (TBE) for people living in and travelling to TBE-endemic areas.
Travel Med Infect Dis
; 6(6): 331-41, 2008 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-18984477
4.
Protection against tick-borne encephalitis with a new vaccine formulation free of protein-derived stabilizers.
J Travel Med
; 12(2): 85-93, 2005.
Artigo
Inglês
| MEDLINE | ID: mdl-15996453
5.
Five year follow-up after a first booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates long-term antibody persistence and safety.
Vaccine
; 32(34): 4275-80, 2014 Jul 23.
Artigo
Inglês
| MEDLINE | ID: mdl-24950352
6.
Tick-borne encephalitis (TBE) trends in epidemiology and current and future management.
Travel Med Infect Dis
; 8(4): 233-45, 2010 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-20970726
7.
Long-term persistence of tick-borne encephalitis antibodies in children 5 years after first booster vaccination with Encepur Children.
Vaccine
; 27(10): 1585-8, 2009 Mar 04.
Artigo
Inglês
| MEDLINE | ID: mdl-19162115
8.
Long-term persistence of tick-borne encephalitis antibodies in adults 5 years after booster vaccination with Encepur Adults.
Vaccine
; 27(6): 853-6, 2009 Feb 05.
Artigo
Inglês
| MEDLINE | ID: mdl-19071180
9.
Tick-born encephalitis (TBE) vaccination in children: advantage of the rapid immunization schedule (i.e., days 0, 7, 21).
Hum Vaccin
; 3(2): 42-7, 2007.
Artigo
Inglês
| MEDLINE | ID: mdl-17297298
10.
Response to tick-borne encephalitis (TBE) booster vaccination after prolonged time intervals to primary immunization with the rapid schedule.
Int J Med Microbiol
; 296 Suppl 40: 208-12, 2006 May.
Artigo
Inglês
| MEDLINE | ID: mdl-16531118
11.
Persistence of antibodies after vaccination against tick-borne encephalitis.
Int J Med Microbiol
; 296 Suppl 40: 202-7, 2006 May.
Artigo
Inglês
| MEDLINE | ID: mdl-16524776
12.
Tick-borne encephalitis vaccines: past and present.
Expert Rev Vaccines
; 4(5): 747-55, 2005 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-16221075
13.
Post-marketing surveillance of immediate allergic reactions: polygeline-based versus polygeline-free pediatric TBE vaccine.
Vaccine
; 23(5): 579-84, 2004 Dec 16.
Artigo
Inglês
| MEDLINE | ID: mdl-15542177
14.
Immediate allergic reactions after vaccinations--a post-marketing surveillance review.
Eur J Pediatr
; 161(1): 21-5, 2002 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-11808876
15.
Long-term immunity after vaccination against tick-borne encephalitis with Encepur using the rapid vaccination schedule.
Int J Med Microbiol
; 293 Suppl 37: 130-3, 2004 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-15146994
16.
TBE booster immunization in adults--first experience with a new tick-borne encephalitis (TBE) vaccine, free of protein-derived stabilizer.
Int J Med Microbiol
; 293 Suppl 37: 134-8, 2004 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-15146995
17.
Clinical evaluation of a polygeline-free tick-borne encephalitis vaccine for adolescents and adults.
Vaccine
; 21(7-8): 738-41, 2003 Jan 30.
Artigo
Inglês
| MEDLINE | ID: mdl-12531352
18.
TBE booster immunization according to the rapid immunization schedule: are 3-year booster intervals really necessary?
Vaccine
; 23(3): 312-5, 2004 Dec 02.
Artigo
Inglês
| MEDLINE | ID: mdl-15530673
19.
Kinetics of the immune response after primary and booster immunization against tick-borne encephalitis (TBE) in adults using the rapid immunization schedule.
Vaccine
; 21(32): 4655-60, 2003 Dec 01.
Artigo
Inglês
| MEDLINE | ID: mdl-14585672
20.
A tick-borne encephalitis vaccine without human serum albumin as stabilizer.
Vaccine
; 23(50): 5699, 2005 Dec 30.
Artigo
Inglês
| MEDLINE | ID: mdl-16226355